FDA Approved: TYGACIL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved a supplemental application for TYGACIL (tigecycline) submitted by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., to update the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Bacterial Pneumonia
• Complicated Intra-abdominal Infection
• Complicated Skin and Skin Structure Infection

Drugs mentioned

• TYGACIL (tigecycline)

Snippet

SUPPL AP for TYGACIL (TIGECYCLINE)